LinkDoc Technology, a Chinese healthcare data company specializing in oncology patients, announced terms for its IPO on Thursday.
The Beijing, China-based company plans to raise $200 million by offering 10.8 million ADSs at a price range of $17.50 to $19.50. Insiders Alibaba Health and Lake Bleu Capital and new investors Temasek Holdings, UBS, Hudson Bay Capital, and Sage Partners have indicated an interest in purchasing an aggregate of $115 million worth of ADSs in the offering (58% of the deal). At the midpoint of the proposed range, LinkDoc Technology would command a fully diluted market value of $1.5 billion.
LinkDoc Technology provides a data-driven and AI-enabled healthcare technology platform that structures cancer patient data to enable precision medicine and personalized care. The company's platform consist of LinkCare, a digital continuous care platform for patients with critical diseases, LinkData, an AI-enabled curation system for longitudinal medical data, and LinkSolutions, a data-driven precision life sciences platform that helps accelerate clinical research. Since 2015, LinkDoc's platform has cumulatively cared for over 3.5 million patients and provided longitudinal care for over 2.5 million patients.
LinkDoc Technology was founded in 2014 and booked $156 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol LDOC. Morgan Stanley, BofA Securities, CICC, Tiger Brokers, and Snowball Securities are the joint bookrunners on the deal.
